skip to main content

NSCLC — SCE Medical Oncology MCQ

Instant feedback + full explanation. One question, done properly.

HardLung CancerNSCLCSCE Medical Oncology

A treatment-naive patient has advanced non-squamous NSCLC with an activating EGFR exon-20 insertion. Under the 2026 NICE managed-access recommendation, which regimen can be offered if its conditions are met?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: B — Amivantamab with carboplatin and pemetrexed

NICE TA1158 permits amivantamab with carboplatin and pemetrexed during managed access for untreated EGFR exon-20-insertion advanced NSCLC. Amivantamab monotherapy is a post-platinum licensing concept, while the other regimens address different EGFR settings or are not the TA1158 regimen.

Reference: NICE TA1158: amivantamab with carboplatin and pemetrexed. https://www.nice.org.uk/guidance/ta1158/chapter/1-Recommendations